NCT06463665Phase 2Recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-02Estimated

Enrollment · participants142Estimated

Source updated2026-06-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Carcinoma; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent

Treatments or interventions studied

Olvimulogene nanivacirepvecBiologicalAlso known as Olvi-Vec, GL-ONC, GLV-1h68
Platinum chemotherapy: carboplatin or cisplatinDrugAlso known as Brand of drug is based on institutional procurement
Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLCDrugAlso known as Brand of drug is based on institutional procurement
Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumabDrugAlso known as Brand of drug is based on institutional procurement
DocetaxelDrugAlso known as Brand of drug is based on institutional procurement

Primary outcomes · main study measures

measure: Progression-free Survival per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR); description: To assess progression-free survival from time of randomization until first documented disease progression based on radiological assessment or death from any cause.; timeFrame: From date of randomization up to 12 months.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history